Tennessee Oncology | Association Partnerships

Benjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.

Results from an age group analysis of the monarch E trial reveal continued efficacy and safety with the experimental regimen, abemaciclib plus endocrine therapy.

In an interview with Targeted Oncology, Meredith McKean, MD, MPH of Sarah Cannon Research Institute reviewed the recent changes to the U.S. Preventive Services Task Force skin cancer screening guidelines, and discussed advances in the skin cancer treatment paradigm for those who could not prevent the disease.

In an interview with Targeted Oncology for Melanoma Monday, Meredith McKean, MD, MPH, discussed recent and upcoming advances in melanoma treatment.

A Tennessee Oncology location in Nashville was the first to dose the novel c-MET antibody-drug conjugate, MYTX-011, as part of the phase 1 KisMET-01 clinical trial.

Benjamin Garmezy, MD, discusses the choice of third-line therapies in patients with advanced renal cell carcinoma.

Erika P. Hamilton, MD, discusses the findings from a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Erika P. Hamilton, MD, discusses the wide-ranging impacts of the introduction of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

Erika P. Hamilton, MD, discusses the evolution of fam-trastuzumab deruxtecan-nxki through its examination in various trials.

Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the key takeaways of the updated safety analysis of the DESTINY-Breast03 trial.

During a Targeted Oncology case-base roundtable event, Jesus G. Berdeja, MD, moderated a discussion around a 55-year-old Black man with late-stage multiple myeloma being treated in a rural community.

The first patient has been dosed in the phase 1 KN-4802 trial examining the safety, tolerability, and preliminary efficacy of KIN-3248 in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

Jesus Berdeja, MD, discusses the safety profile observed with the newly approved chimeric antigen receptor T-cell therapy, ciltacabtagene autoleucel as observed in the phase 1/2 CARTITUDE-1 clincial trial.

Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.

In an interview, Jesus Berdeja, MD, discussed the introduction of ciltacabtagene autoleucel into the treatment landscape for relapsed/refractory multiple myeloma, how it may differ from idecabtagene vicleucel, and the future of CAR T-cell use in the space.

Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma.

How an oncologist treats a patients with non–small cell lung cancer wit the available treatment options is largely dependent on the patient's PD-L1 status.

During a Targeted Oncology Case-Based Roundtable event, Melissa L. Johnson, MD, director, discussed the case of 66-year-old man with non–small cell lung cancer.

An innovative value-based cancer care program has been launched to improve treatment coordination for thousands of patients in Tennessee.

Meredith McKean, MD, MPH, moderated a Case-Based Roundtable discussion about a 88-year-old patient with Basel cell carcinoma.

For World Cancer Day, Jeff Patton, MD, discusses COVID-19’s impact on cancer treatment and testing in an interview with Targeted Oncology.

Targeted Oncology, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, announces the addition of Tennessee Oncology to their Strategic Alliance Partnership program.